Chimeric antigen receptor T-cell therapy, or CAR T, has made a big impact on the treatment of certain blood cancers, allowing patients with relapsed/refractory disease to live longer, healthier lives. But in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor
Graphical abstract showing how TALEDs work in mitochondria. First, adenine is deaminated to inosine. Next, inosine is converted to guanine by DNA repair or replication. Scientists successfully achieve A to G base conversion, the final missing piece of the puzzle in gene-editing technology Researchers from the Center for Genome Engineering within the Institute for Basic
The research group led by Professor Misao Fujita conducted a study to estimate the total amount of refund the Japanese government would pay if a patient received unproven cell interventions and applied for a medical expense deduction. Some regenerative medicines whose safety and efficacy have not been fully confirmed in clinical trials and other studies are offered
Key Takeaways Acute myeloid leukemia is the most common leukemia in adults. CAR T cell therapy has made significant inroads against leukemias and lymphomas arising from B cells, but have been largely ineffective against leukemias arising from myeloid cells. MGH investigators have devised a novel method for improving CAR T therapy through a drug combination
A new study compares the regenerative potential of blood/bone marrow aspirate concentrates obtained from arterial blood, venous blood, and bone marrow aspirate. The study, conducted in rabbits, is reported in the peer-reviewed journal Tissue Engineering Part A. Blood concentrate material such as platelet-rick fibrin (PRF) is used in clinical practice to promote tissue regeneration in the
Cedars-Sinai Investigators Found It Also Reduced Scarred Heart Tissue in Animals Vesicles secreted from human heart cells may repair damaged tissue and prevent lethal heart rhythm disorders, according to a new study from investigators in the Smidt Heart Institute at Cedars-Sinai. The research, published in the European Heart Journal, could lead to a new way to
Cell Therapy Developed by Smidt Heart Institute Leader Delays Disease Progression in Patients Who Have Few Treatment Options A cell therapy developed by the executive director of the Smidt Heart Institute stabilizes weakened muscles–including the heart muscle–in Duchenne muscular dystrophy patients, a new study published in the international peer-reviewed journal The Lancet shows. If the HOPE-2 study’s
A new study by University of Manitoba researchers has developed a stem cell-based therapy that may eventually lead to new regenerative treatments for people with spinal cord injuries. Dr. Soheila Karimi, professor of physiology and pathophysiology at the Max Rady College of Medicine, Rady Faculty of Health Sciences, and her colleagues have developed a treatment strategy that
On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma. Approval was
Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13. “We were favorably surprised by the
